Quantitative reverse transcription polymerase chain reaction (qRT-PCR) validated expression differences of key protein biomarkers at the tissue level, providing experimental evidence that enhances the credibility of the findings and more robustly supports the greater potential of SLC11A1 as a biomarker for NAFLD. The gene discussed is SLC11A1; the disease is metabolic dysfunction-associated steatotic liver disease.